Role of Plant Metabolomics in Drug Discovery

Dr. Joon-Ho Kim [1*], Dr. Min-Seo Lee [2], Dr. Soo-Jin Park [3]
[1] Seoul National University, Nanomedicine Research Center, South Korea
[2] KAIST, Drug Delivery Engineering Lab, South Korea
[3] Yonsei University, Precision Oncology Nanotechnology Unit, South Korea

* Corresponding Author: **Dr. Joon-Ho Kim**

Article Info

ISSN (online): 3107-393X
Volume: 02
Issue: 03
May-June 2025
Received: 19-03-2025
Accepted: 22-04-2025
Published: 18-05-2025
Page No: 48-54

Abstract
Plant-derived natural products have historically constituted a foundational resource for pharmaceutical development, and the emergence of metabolomics as a systems-level analytical discipline has substantially augmented the capacity to explore plant chemical diversity in the context of drug discovery. Metabolomics enables the comprehensive, simultaneous analysis of low-molecular-weight metabolites present in biological systems, thereby providing an integrated biochemical portrait of plant organisms under defined physiological or experimental conditions. The objective of this review is to critically examine the role of plant metabolomics in modern drug discovery, with emphasis on the analytical methodologies that underpin metabolite identification and quantification, the integration of metabolomic data with complementary omics platforms, and the translational potential of metabolomic findings from bench to clinical and industrial application. Advanced analytical techniques including liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry, high-resolution mass spectrometry, and nuclear magnetic resonance spectroscopy are systematically discussed in relation to their capabilities and limitations in the profiling of plant secondary metabolites. The review further addresses bioinformatic challenges associated with large-scale metabolomic datasets, the use of metabolomics in biomarker discovery and lead compound identification, and the regulatory and reproducibility considerations that govern the translation of plant metabolomic findings into pharmaceutical products. Future perspectives highlight the convergence of artificial intelligence, multi-omics integration, and green chemistry principles as transformative forces in metabolomics-driven drug discovery.

Keywords: Plant metabolomics, Drug discovery, Metabolite profiling, Natural products, Systems biology, Translational research

1. Introduction

The historical reliance of pharmacology on natural products as sources of therapeutic agents is well documented, with estimates suggesting that more than half of all approved drugs introduced since 1981 are derived from or inspired by natural compounds, predominantly those of plant origin [4, 5]. The chemical complexity inherent in plant secondary metabolism, which encompasses thousands of structurally diverse alkaloids, terpenoids, flavonoids, phenylpropanoids, and polyketides, has long served as a library of bioactive scaffolds for pharmaceutical lead discovery [6]. Nevertheless, the systematic and efficient exploitation of this chemical reservoir has historically been constrained by the limitations of classical phytochemical approaches, which are inherently reductive, time-consuming, and biased toward abundant or previously characterised compounds [7].

Metabolomics, defined as the comprehensive, unbiased measurement of all low-molecular-weight metabolites within a biological system at a given time point, has emerged over the past two decades as a transformative platform for the investigation of plant biochemistry and its pharmacological applications [8]. As the terminal readout of gene expression and cellular function,

the metabolome provides a functional snapshot of plant physiology that is directly relevant to the identification of bioactive compounds, the understanding of biosynthetic pathways, and the assessment of plant quality in relation to medicinal utility [9, 10]. The integration of metabolomics with genomics, transcriptomics, and proteomics within the broader framework of systems biology has further enhanced its explanatory power, enabling the elucidation of complex genotype-phenotype relationships and the discovery of previously uncharacterised metabolic pathways relevant to drug discovery [11].

This review aims to provide a comprehensive and critically analytical account of the role of plant metabolomics in drug discovery. The discussion proceeds from the foundational principles of metabolomics methodology through the analytical technologies that enable metabolite detection and identification, and culminates in a synthesis of current and emerging applications in lead compound discovery, biomarker identification, and herbal medicine standardisation. Particular attention is paid to the challenges of data analysis, translational application, and regulatory compliance that must be addressed to realise the full potential of plant metabolomics as a drug discovery tool [12].

2. Fundamentals of Plant Metabolomics

Metabolomics can be broadly categorised into targeted and untargeted approaches, each defined by distinct analytical objectives, methodological requirements, and interpretive frameworks [13]. Targeted metabolomics is concerned with the accurate quantification of a predefined set of metabolites, selected on the basis of prior biological knowledge or pharmacological relevance. This approach affords high analytical sensitivity and specificity, permitting absolute quantification of selected analytes within complex plant matrices, and is particularly suited to the validation of candidate biomarkers or the quality control of herbal preparations [14]. However, its inherent restriction to known metabolites limits its capacity for discovery and precludes the identification of novel bioactive compounds that fall outside the predefined analyte panel.

Untargeted metabolomics, by contrast, adopts a hypothesis-generating, global profiling strategy that seeks to detect as many metabolites as possible without prior specification of analyte identity [15]. This approach is inherently discovery-oriented and has been instrumental in identifying novel plant secondary metabolites with potential pharmacological activity. The principal challenge of untargeted metabolomics lies in the annotation and biological interpretation of the vast number of detected features, many of which remain uncharacterised due to the incompleteness of existing metabolite databases and the structural complexity of natural products [16]. The complementarity of targeted and untargeted approaches is increasingly recognised, and integrated metabolomic strategies that combine both paradigms are now widely employed in plant drug discovery programmes [17].

Plant metabolomics presents unique challenges relative to mammalian metabolomics, arising from the extraordinary chemical diversity of plant secondary metabolites, the dependence of metabolome composition on developmental stage, tissue type, growth conditions, and environmental stressors, and the technical difficulties associated with extracting and analysing structurally heterogeneous compound classes from complex plant matrices [18]. Standardisation of sample collection, storage, and extraction protocols is therefore of paramount importance in plant metabolomic studies, as pre-analytical variability can significantly confound downstream data analysis and biological interpretation [19].

Table 1: Comparison of targeted and untargeted metabolomics approaches.

Criterion	Targeted Metabolomics	Untargeted Metabolomics
Objective	Quantification of predefined metabolites	Comprehensive, hypothesis-free profiling
Coverage	Limited to known metabolites	Broad spectrum including unknowns
Sensitivity	High; optimised for specific analytes	Moderate to high; compound-dependent
Selectivity	High	Variable
Quantification	Absolute quantification feasible	Primarily semi-quantitative
Data complexity	Low to moderate	High
Bioinformatics needs	Moderate	Extensive
Typical platforms	Triple quadrupole MS, HPLC-MS/MS	HRMS (Orbitrap, Q-TOF), NMR
Applications in drug discovery	Biomarker validation, QC of extracts	Lead identification, metabolite discovery
Advantages	Reproducible, clinically translatable	Discovery-driven, unbiased
Limitations	Misses novel metabolites; requires prior knowledge	Annotation bottleneck; complex data handling

3. Analytical Techniques in Plant Metabolomics

The analytical foundation of plant metabolomics rests upon a suite of highly sensitive and selective instrumental techniques, of which mass spectrometry and nuclear magnetic resonance spectroscopy constitute the principal platforms [20]. Each technique offers a distinct combination of sensitivity, structural resolution, throughput, and quantitative capability, and the selection of an appropriate analytical strategy is dictated by the nature of the research question, the complexity of the plant matrix, and the available instrumentation [21].

Liquid chromatography-mass spectrometry, and in particular ultra-performance liquid chromatography coupled to tandem mass spectrometry, has become the predominant analytical platform in plant metabolomics owing to its exceptional sensitivity, broad metabolite coverage, and compatibility with non-volatile, thermolabile plant secondary metabolites including alkaloids, flavonoids, saponins, and glucosinolates [22]. The coupling of high-resolution mass spectrometric analysers, such as quadrupole time-of-flight instruments and Orbitrap-based systems, to liquid chromatographic separation affords accurate mass measurement at sub-parts-per-million resolution, enabling the determination of molecular formulae and the tentative identification of novel metabolites through database matching [23]. Gas chromatography-mass spectrometry remains indispensable for the profiling of volatile compounds, essential oil constituents, fatty acids, and derivatisable polar metabolites

such as amino acids and organic acids, offering excellent chromatographic resolution and the benefit of reproducible, library-matchable electron ionisation fragmentation spectra [24].

Nuclear magnetic resonance spectroscopy occupies a complementary and irreplaceable role in plant metabolomics, particularly in the unambiguous structural elucidation of isolated natural products and the quantitative profiling of primary metabolites in complex plant extracts [25]. Unlike mass spectrometry-based methods, NMR is inherently quantitative without requiring reference standards, non-destructive, and capable of providing comprehensive three-dimensional structural information that cannot be obtained from mass spectral data alone. The principal limitation of NMR in metabolomics applications is its comparatively low sensitivity relative to mass spectrometry, necessitating relatively large sample quantities and restricting its application in the detection of trace-level secondary metabolites [26]. The development of hyphenated techniques such as high-performance liquid chromatography-nuclear magnetic resonance and LC-NMR-MS has partially addressed this limitation by combining the separation power of chromatography with the structural resolution of both NMR and mass spectrometry in a single analytical workflow [27].

Table 2: Summary of analytical techniques used in plant metabolomics and their applications in drug discovery.

Technique	Principle	Key Strengths	Limitations	Applications in Drug Discovery
LC-MS/MS	Liquid chromatography coupled to tandem MS	High sensitivity, selectivity, reproducibility	Matrix effects, suppression	Alkaloid, flavonoid, terpenoid profiling
GC-MS	Gas chromatography with electron ionisation MS	Excellent for volatile and derivatisable compounds	Limited to volatile analytes	Essential oils, fatty acids, amino acids
HRMS (Orbitrap/Q-TOF)	High-resolution accurate mass spectrometry	Elemental composition, de novo identification	High cost, complex spectra	Untargeted discovery, unknown annotation
1H-NMR	Proton nuclear magnetic resonance	Non-destructive, structural elucidation	Lower sensitivity than MS	Structural confirmation, QC
13C-NMR	Carbon-13 NMR spectroscopy	Comprehensive carbon skeleton data	Low sensitivity, long acquisition time	Complete structural assignment
UPLC-MS	Ultra-performance liquid chromatography-MS	Rapid analysis, high throughput	Requires method optimisation	High-throughput screening
CE-MS	Capillary electrophoresis coupled to MS	Low sample volume, polar metabolites	Limited robustness	Amino acids, organic acids
DART-MS	Direct analysis in real time MS	Minimal sample preparation	Lower resolution	Rapid screening of crude extracts

4. Metabolomics and Bioactive Compound Discovery

The application of plant metabolomics to the identification of bioactive compounds represents one of the most significant contributions of the discipline to pharmaceutical science. Untargeted metabolomic profiling of plant extracts, when combined with bioactivity-guided fractionation or statistical correlation analysis, provides a powerful framework for the prioritisation of metabolite fractions enriched in pharmacologically active constituents and the rapid dereplication of previously characterised compounds [28]. Multivariate statistical approaches, including principal component analysis, orthogonal partial least squares-discriminant analysis, and hierarchical clustering, are routinely employed to identify metabolites that discriminate between bioactive and inactive fractions or that correlate with specific pharmacological endpoints [29].

The integration of metabolomics with genomics and transcriptomics has yielded particularly powerful synergies in the context of biosynthetic pathway elucidation. Genome mining approaches, which exploit the availability of fully sequenced plant genomes to identify biosynthetic gene clusters encoding enzymes of secondary metabolite pathways, can be directed by metabolomic data to prioritise pathways associated with biologically relevant compound classes [30]. Conversely, transcriptomic analysis of plants subjected to elicitation or environmental stress, interpreted in conjunction with corresponding metabolomic profiles, enables the construction of regulatory networks linking gene expression changes to metabolite accumulation and thereby facilitates the discovery of novel biosynthetic routes to pharmacologically important natural products [31]. Proteomics provides an additional layer of functional annotation by linking the protein complement of a cell to its metabolic output, and multi-omics data integration platforms increasingly enable the simultaneous analysis of metabolomic, proteomic, and genomic datasets within a unified systems biology framework [32].

Recent advances in activity metabolomics, which couples metabolite profiling directly to *in vitro* or *in vivo* pharmacological assays, have enabled the correlation of specific metabolite features with observed biological activities in a hypothesis-generating manner [33]. This approach has been successfully applied to the identification of anti-infective, anti-inflammatory, anticancer, and neuroprotective compounds from diverse plant species, demonstrating the capacity of metabolomics to accelerate the early stages of natural product drug discovery by narrowing the chemical space requiring detailed pharmacological investigation [34].

5. Data Analysis and Bioinformatics

The analysis of large-scale metabolomic datasets presents substantial computational and interpretive challenges that represent a critical bottleneck in the translation of metabolomic findings into pharmacologically actionable knowledge. Raw data generated by high-resolution mass spectrometric platforms typically comprise millions of spectral features per sample, necessitating multi-stage data processing pipelines encompassing noise filtering, peak detection, alignment, normalisation, and adduct annotation prior to biological interpretation [35]. Software platforms including MZmine, XCMS, and MetaboAnalyst have been

widely adopted for these purposes and offer varying degrees of automation, customisation, and downstream statistical analysis capability [36].

Metabolite annotation, defined as the assignment of putative chemical identities to detected mass spectral features, remains a persistent challenge in untargeted plant metabolomics owing to the structural diversity of plant secondary metabolites, the incompleteness of reference databases, and the complexity of fragmentation patterns arising from isobaric and isomeric species [37]. The Metabolomics Standards Initiative has established a hierarchical reporting framework for metabolite identification confidence levels, ranging from confirmed identification by reference standard to putative annotation based on spectral library matching, and adherence to these standards is essential for the reproducibility and comparability of published metabolomic data [38]. The development of in silico fragmentation prediction tools such as CFM-ID, SIRIUS, and MetFrag has partially alleviated the annotation burden by enabling the automated comparison of experimental fragmentation spectra against computationally generated reference spectra, thereby extending the coverage of spectral databases to include metabolites lacking authentic reference standards [39].

Machine learning and artificial intelligence approaches are increasingly being applied to metabolomic data analysis, offering potential improvements in classification accuracy, biomarker discovery, and predictive modelling relative to classical statistical methods. Deep learning architectures trained on large annotated metabolomic datasets have demonstrated promising performance in metabolite identification, biological activity prediction, and quality control applications, though the requirement for large, well-annotated training datasets remains a limiting factor in plant metabolomic contexts where reference data are relatively sparse [40].

6. Applications in Drug Discovery

The application of plant metabolomics to drug discovery encompasses a spectrum of activities ranging from early-stage lead identification through preclinical pharmacological characterisation to the quality assurance and standardisation of plant-based pharmaceutical products. In the lead identification phase, untargeted metabolomic profiling of taxonomically diverse plant species, guided by ethnobotanical knowledge or chemotaxonomic principles, enables the systematic survey of plant chemical space for novel bioactive scaffolds and the identification of metabolite correlates of observed pharmacological activity [4]. The dereplication of known compounds through database-matched spectral annotation prevents the redundant reinvestigation of previously characterised natural products and allows research effort to be focused on genuinely novel chemical entities [28].

Biomarker discovery represents a further major application of plant metabolomics in pharmaceutical contexts. The identification of metabolite profiles that distinguish medicinal plant species, chemotypes, or geographical varieties of pharmacological relevance supports the authentication and quality control of herbal raw materials and finished products, thereby addressing the significant quality variability that characterises the herbal medicine supply chain [17]. Metabolomic fingerprinting approaches have been applied to the authentication of valuable medicinal plant species including Panax ginseng, Curcuma longa, and Artemisia annua, enabling the rapid discrimination of authentic material from adulterants and the chemotypic characterisation of cultivated germplasm [19].

The application of metabolomics to the standardisation of herbal medicines addresses one of the most significant challenges in phytopharmaceutical development, namely the demonstration of consistent composition, potency, and safety across production batches. Metabolomic quality control platforms, which combine comprehensive chemical profiling with multivariate statistical models trained on reference material of established quality, enable the objective assessment of batch-to-batch reproducibility and the identification of out-of-specification material prior to further processing [14]. This approach is complementary to, and more informative than, conventional phytochemical quality markers, which capture only a fraction of the total chemical complexity of plant materials [18].

Figures



Fig 1: Schematic representation of the plant metabolomics workflow, encompassing the sequential stages of experimental design and plant material collection



Fig 2: Conceptual diagram illustrating the integration of metabolomics with complementary omics disciplines within a systems biology framework for drug discovery.



Fig 3: Overview of the application of plant metabolomics in the identification and development of plant-derived therapeutic compounds

7. Translational and Industrial Applications

The translation of plant metabolomic discoveries from research settings to industrial pharmaceutical or nutraceutical applications requires careful consideration of standardisation, reproducibility, and regulatory compliance across the entire production chain. The inherent variability of plant raw materials, arising from genetic diversity, environmental conditions, harvesting practices, and post-harvest processing, necessitates robust metabolomic quality assurance frameworks capable of detecting and characterising compositional deviations that may affect product efficacy or safety [21]. Industrial adoption of metabolomics-based quality control has been reported by several phytopharmaceutical manufacturers, with applications spanning incoming raw material testing, in-process monitoring, and finished product release [17].

Reproducibility remains a central challenge in plant metabolomics, as technical variables including instrument calibration, column ageing, mobile phase composition, and operator-dependent sample preparation can introduce systematic biases that confound inter-laboratory comparisons and impede the validation of metabolomic methods for regulatory purposes [36]. The development and adoption of standardised operating procedures, the use of certified reference materials, and participation in inter-laboratory proficiency testing programmes are essential measures for ensuring the analytical reproducibility required in regulated pharmaceutical environments [38]. Regulatory agencies including the European Medicines Agency and the United States Food and Drug Administration have begun to engage with metabolomics as a tool for plant medicine quality control, though formal guidelines specifically addressing metabolomic methodology in this context remain limited [14].

8. Critical Limitations and Challenges

Notwithstanding its considerable potential, plant metabolomics is subject to a range of technical, analytical, and regulatory limitations that temper the translation of its research outputs into applied pharmaceutical settings. At the technical level, no single analytical platform provides comprehensive coverage of the entire plant metabolome, owing to the physicochemical diversity of plant secondary metabolites and the differential ionisation efficiencies and chromatographic behaviours of compounds from different chemical classes [20]. The use of complementary analytical platforms in combination partially addresses this limitation but substantially increases analytical cost, instrument time, and data management complexity [27].

The annotation of unknown metabolites constitutes perhaps the most significant analytical bottleneck in untargeted plant metabolomics. It is estimated that only a minority of detected mass spectral features in plant metabolomic datasets can be confidently annotated using available spectral libraries, which remain substantially incomplete relative to the diversity of plant secondary metabolites that have been structurally characterised by classical phytochemistry [16]. The challenge is compounded by the prevalence of structural isomers and stereoisomers among plant natural products, which may exhibit identical or highly similar mass spectra yet possess markedly different pharmacological properties [37]. The development of expanded, curated metabolite databases and the application of advanced computational annotation tools represent priority areas for methodological development in the field [39].

Regulatory and ethical challenges also merit consideration. The demonstration of equivalence between plant

metabolomic quality control methods and pharmacopoeial standards currently specified for herbal medicines requires extensive validation against established phytochemical reference methods, and the resource requirements for such validation represent a significant barrier for smaller research institutions and developing-world producers of medicinal plant products [35]. Additionally, questions of intellectual property and benefit-sharing arising from the metabolomic investigation of plant genetic resources from biodiversity-rich regions are governed by the Nagoya Protocol and associated national legislation, and compliance with these frameworks is an essential but often complex requirement in plant metabolomics research with commercial intent [6].

9. Conclusions and Future Directions

Plant metabolomics has matured into an analytically sophisticated and scientifically powerful discipline that occupies a central position in contemporary natural product drug discovery. The integration of advanced mass spectrometric and NMR-based analytical platforms with robust bioinformatic pipelines and multi-omics data integration strategies has substantially expanded the capacity of plant metabolomic investigations to generate pharmacologically relevant discoveries, from the identification of novel bioactive compounds and the elucidation of their biosynthetic origins to the standardisation and authentication of plant-based medicinal products [10, 31].

Looking forward, several emerging developments are poised to further transform the landscape of metabolomics-driven drug discovery. The rapid expansion of artificial intelligence and machine learning applications in metabolomic data analysis promises to accelerate metabolite annotation, enhance the accuracy of biological activity prediction from chemical structural data, and enable the construction of predictive models that link plant genotype, metabolome composition, and pharmacological outcome across large and diverse plant collections [40]. The continued development of spatial metabolomics technologies, including desorption electrospray ionisation and matrix-assisted laser desorption ionisation mass spectrometry imaging, will enable the mapping of metabolite distributions within plant tissues at cellular resolution, providing new insights into the organ-specific accumulation of bioactive compounds and their relationship to plant defence mechanisms and biosynthetic specialisation [23].

The convergence of plant metabolomics with synthetic biology and metabolic engineering offers the prospect of transferring biosynthetic pathways for pharmacologically important plant natural products into tractable microbial production hosts, thereby overcoming the supply constraints and environmental pressures associated with the cultivation and harvesting of medicinal plant species [30]. Realising this vision will require continued advances in the metabolomic characterisation of plant biosynthetic pathways, the functional annotation of biosynthetic enzymes, and the development of robust fermentation and downstream processing technologies adapted to the structural complexity of plant-derived natural products. In aggregate, these advances position plant metabolomics as an indispensable and increasingly powerful tool in the discovery and development of next-generation plant-derived medicines [11, 32].

References

1. Verpoorte R, Choi YH, Kim HK. NMR-based metabolomics at work in phytochemistry. Phytochemistry Reviews. 2007;6(1):3–14.
2. Fiehn O. Metabolomics: the link between genotypes and phenotypes. Plant Molecular Biology. 2002;48(1–2):155–171.
3. Hall RD. Plant metabolomics: from holistic hope to hype, to hot topic. New Phytologist. 2006;169(3):453–468.
4. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products. 2020;83(3):770–803.
5. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery. 2015;14(2):111–129.
6. Verpoorte R, Heijden R, Memelink J. Engineering the plant cell factory for secondary metabolite production. Transgenic Research. 2000;9(4–5):323–343.
7. Wolfender JL, Marti G, Thomas A, Bertrand S. Current approaches and challenges for the metabolite profiling of complex natural extracts. Journal of Chromatography A. 2015;1382:136–164.
8. Weckwerth W. Metabolomics in systems biology. Annual Review of Plant Biology. 2003;54:669–689.
9. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008;455(7216):1054–1056.
10. Sumner LW, Mendes P, Dixon RA. Plant metabolomics: large-scale phytochemistry in the functional genomics era. Phytochemistry. 2003;62(6):817–836.
11. Fernie AR, Trethewey RN, Krotzky AJ, Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nature Reviews Molecular Cell Biology. 2004;5(9):763–769.
12. Oksman-Caldentey KM, Saito K. Integrating genomics and metabolomics for engineering plant metabolic pathways. Current Opinion in Biotechnology. 2005;16(2):174–179.
13. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrometry Reviews. 2007;26(1):51–78.
14. Gao W, Meng Q, Cai Q, Fang M. Metabolomics-based quality control of herbal medicines. Frontiers in Pharmacology. 2020;11:583395.
15. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nature Reviews Drug Discovery. 2016;15(7):473–484.
16. Allwood JW, Goodacre R. An introduction to liquid chromatography-mass spectrometry instrumentation applied in plant metabolomic analyses. Phytochemical Analysis. 2010;21(1):33–47.
17. Verpoorte R, Choi YH, Mustafa NR, Kim HK. Metabolomics: back to basics. Phytochemistry Reviews. 2008;7(3):525–537.
18. Kim HK, Choi YH, Verpoorte R. NMR-based plant metabolomics: where do we stand, where do we go? Trends in Biotechnology. 2011;29(6):267–275.
19. Choi YH, Kim HK, *et al*. NMR metabolomics to revisit the tobacco mosaic virus infection in Nicotiana tabacum

leaves. Journal of Natural Products. 2006;69(5):742–748.
20. Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. TrAC Trends in Analytical Chemistry. 2005;24(4):285–294.
21. Moing A, Maucourt M, *et al*. Quantitative metabolic profiling by 1D 1H-NMR analyses: application to plant genetics and functional genomics. Functional Plant Biology. 2004;31(9):889–902.
22. Jacobs A, Lunde C, Bacic A, Tenkanen M, Andersson R. The impact of choice of sample preparation and extraction methods on plant cell wall glycosidic linkages. Journal of Agricultural and Food Chemistry. 2009;57(3):816–822.
23. Alexandrov T. Spatial metabolomics and imaging mass spectrometry in the age of artificial intelligence. Annual Review of Biomedical Data Science. 2020;3:61–87.
24. Roessner U, Luedemann A, *et al*. Metabolic profiling allows comprehensive phenotyping of plant systems. Plant Cell. 2001;13(1):11–29.
25. Robinette SL, Bruschweiler R, *et al*. NMR in metabolomics and natural products research: two sides of the same coin. Accounts of Chemical Research. 2012;45(2):288–297.
26. Markley JL, *et al*. The future of NMR-based metabolomics. Current Opinion in Biotechnology. 2017;43:34–40.
27. Exarchou V, Godejohann M, *et al*. LC-UV-SPE-NMR-MS applied to Greek oregano compounds. Analytical Chemistry. 2003;75(22):6288–6294.
28. Wolfender JL, Ndjoko K, Hostettmann K. LC-UV-MS and NMR for plant metabolite investigation. Journal of Chromatography A. 2003;1000(1–2):437–455.
29. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. Journal of Proteome Research. 2007;6(2):469–479.
30. Oksman-Caldentey KM, Inze D. Plant cell factories in the post-genomic era. Trends in Plant Science. 2004;9(9):433–440.
31. De Vos RC, *et al*. Untargeted plant metabolomics using LC-MS. Nature Protocols. 2007;2(4):778–791.
32. Sanchez DH, *et al*. Plant metabolomics reveals metabolic responses to salinity. Physiologia Plantarum. 2008;132(2):209–219.
33. Piotto S, *et al*. Metabolomics in natural product drug discovery. Current Topics in Medicinal Chemistry. 2016;16(15):1712–1720.
34. Lee MS, *et al*. Effects of capsaicin on lipid catabolism. Phytotherapy Research. 2011;25(6):935–939.
35. Vinaixa M, *et al*. Mass spectral databases for metabolomics. TrAC Trends in Analytical Chemistry. 2016;78:23–35.
36. Tautenhahn R, *et al*. XCMS Online platform for metabolomics. Analytical Chemistry. 2012;84(11):5035–5039.
37. Schymanski EL, *et al*. Identifying small molecules via HRMS. Environmental Science & Technology. 2014;48(4):2097–2098.
38. Sumner LW, *et al*. Minimum reporting standards for chemical analysis. Metabolomics. 2007;3(3):211–221.
39. Dührkop K, *et al*. SIRIUS 4 for metabolite structure elucidation. Nature Methods. 2019;16(4):299–302.
40. Liebal UW, *et al*. Machine learning in mass spectrometry-based metabolomics. Metabolites. 2020;10(6):243.